glp 1 agonist in pregnancy Obstetrics & Gynecology | “With rising obesity rates and increasing glucagon-like peptide-1 receptor (GLP-1 RA) use, understanding perinatal prescribing GLP-1s (Weight loss injections) AND

The combined receptor activation produces measurable outcomes distinct from single or dual-receptor activation alone

Chemical modifications, such as amino acid mutations, addition of fatty acid chains, or design of synthetic analogs, can enhance their resistance to enzymatic degradation and significantly improve metabolic stability and half-life (Yu et al., 2018

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease

Norgaard, C

Neuroprotective Benefits of GLP-1R Agonists and DPP-4 Inhibitors: Anti-Inflammatory and Antioxidant Mechanisms 6.1

This outcome also exceeded the weight loss observed in the active comparator group treated with liraglutide 3.0 mg, a once-daily GLP-1 RA (10.8% vs